Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medtronic PLC (MDT) vs T-Mobile Us Inc (TMUS) Price & Performance

Medtronic PLCTrade
T-Mobile Us IncTrade

Price performance (Past 24H)

Key statistics

Medtronic PLC vs T-Mobile Us Inc — how do they compare? Medtronic PLC trades at $90.61 (market cap $116.07B), while T-Mobile Us Inc trades at $177.13 (market cap $191.56B). The key difference: T-Mobile Us Inc is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.

MDTTMUS
Market Cap
$116.07B$191.56B
Sector
HealthMedia
52-Week High
$105.35$259.01
52-Week Low
$73.75$167.65
Enterprise Value
$134.82B$308.17B
Dividend Yield
3.18%2.28%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medtronic PLC

Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.

The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.

T-Mobile Us Inc

TMUS trades at $177.02, down 0.64% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.99 actual vs. $2.59 expected, and raised its free cash flow outlook. Revenue growth remains robust, reaching $88.31 billion in 2025, though net income dipped slightly to $10.99 billion. Recent news includes the completion of an $2.9 billion spectrum sale to Grain Management and competitive concerns from SpaceX's Starlink Mobile expansion.

The outlook for TMUS is mixed; strong fundamentals and analyst bullishness with an $233.20 price target suggest upside, but technical bearishness and competitive threats from new entrants like SpaceX pose risks. Earnings momentum and dividend growth support long-term value, yet near-term volatility may persist due to market sentiment and industry disruption.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT

About T-Mobile Us Inc

Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.

Read more on TMUS